A phase 2 trial of dexamethasone, fOLFOX (5-FU, leucovorin, oxaliplatin), fluorouracil (5-FU), fOLFIRI (5-FU, leucovorin, irinotecan) and other drugs in colorectal cancer, run by Sun Yat-sen University, now recruiting.
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients is a phase 2, randomised interventional study registered as NCT05727163 by Sun Yat-sen University, with a registry enrolment figure of 194 participants, started 2022-07-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Dexamethasone; Anisodamine; Oxaliplatin; Leucovorin; Fluorouracil; Irinotecan; Bevacizumab; Oxaliplatin; Leucovorin; Fluorouracil. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Remission Rate (ORR). Colorectal eligibility wording from the registry: "Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.